Home
Market News
Breaking stock market headlines
Earnings Flash
Breaking coverage of earnings reports, forecasts & dividend updates
Trends
Market movers, trading patterns & key market indicators
Disclosures
Official filings & reports from listed Japanese companies
Explorer
Stock lists filtered by fundamental & technical metrics
Sumitomo Pharma, The Current Fiscal Year Net Income Turns to Profit, Exceeds Expectations
4506 Sumitomo Pharma Co., Ltd. 【IFRS】
Earnings ReportSumitomo Pharma Co., Ltd. <4506> [TSE Prime] announced its financial results (based on IFRS) after the market closed on January 31st (15:30). The consolidated net income/loss for the cumulative third quarter of the fiscal year ending March 2025 (April to December) turned into a profit of 21.2 billion yen (compared to a loss of 117 billion yen in the same period last year).
In addition, the full-year consolidated net income has been revised upward from an expected loss of 16 billion yen to a profit of 16 billion yen (compared to a loss of 314 billion yen in the previous period), turning to a profit.
Based on the full-year plan announced by the company after the upward revision, our estimate of the consolidated net income for the October to March period (2H) is expected to increase 3.0 times, from the previous forecast of 16.2 billion yen to 48.2 billion yen (compared to a loss of 247 billion yen in the same period of the previous year).
In the most recent three-month period, from October to December (3Q), the consolidated net income/loss turned to a profit of 53.4 billion yen (compared to a loss of 49.9 billion yen in the same period last year). The operating profit/loss margin drastically improved from -37.9% in the same period last year to 19.0%.
Kabutan News
Actual Results
Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Progress Rate vs. First Half | Announce | Accounting Standards |
---|---|---|---|---|---|---|---|---|
Apr - Dec, 2022 | 460,265 | -17,777 | 2,192 | -18,502 | -46.6 | ー | Jan 31, 2023 | IFRS |
Apr - Dec, 2023 | 235,028 | -117,745 | -105,191 | -117,708 | -296.3 | ー | Jan 31, 2024 | IFRS |
Apr - Dec, 2024 | 293,183 | 13,226 | 24,026 | 21,219 | 53.4 | ー | Jan 31, 2025 | IFRS |
YoY | +24.7% | - | - | - | - |
Guidance Update
Second Half Update
Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Adj. Dividend | Announce | Accounting Standards |
---|---|---|---|---|---|---|---|---|
Oct - Mar, 2024 Prev | 157,251 | 8,179 | ー | 16,229 | 40.9 | 0 | Oct 30, 2024 | IFRS |
Oct - Mar, 2024 New | 200,251 | 29,179 | ー | 48,229 | 121.4 | 0 | Jan 31, 2025 | IFRS |
Revision Rate | +27.3% | +256.8% | - | +197.2% | +197.2% |
Full Year Update
Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Adj. Dividend | Announce | Accounting Standards |
---|---|---|---|---|---|---|---|---|
Mar, 2025 Prev | 338,000 | 0 | ー | -16,000 | -40.3 | 0 | May 14, 2024 | IFRS |
Mar, 2025 New | 381,000 | 21,000 | ー | 16,000 | 40.3 | 0 | Jan 31, 2025 | IFRS |
Revision Rate | +12.7% | - | - | - | - |
Current Period Guidance
Second Half Results
Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Adj. Dividend | Announce | Accounting Standards |
---|---|---|---|---|---|---|---|---|
Oct - Mar, 2023 | 161,916 | -268,361 | -266,987 | -247,228 | -622.3 | 0 | May 14, 2024 | IFRS |
Oct - Mar, 2024 Guidance | 200,251 | 29,179 | ー | 48,229 | 121.4 | 0 | Jan 31, 2025 | IFRS |
YoY | +23.7% | - | - | - | - |
Current Period Guidance
Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Adj. Dividend | Announce | Accounting Standards |
---|---|---|---|---|---|---|---|---|
Mar, 2023 | 555,544 | -76,979 | -47,920 | -74,512 | -187.6 | 21 | May 15, 2023 | IFRS |
Mar, 2024 | 314,558 | -354,859 | -323,114 | -314,969 | -792.8 | 0 | May 14, 2024 | IFRS |
Mar, 2025 Guidance | 381,000 | 21,000 | ー | 16,000 | 40.3 | 0 | Jan 31, 2025 | IFRS |
YoY | +21.1% | - | - | - | - |
Quarterly Results
Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Operating Profit Margin | Announce | Accounting Standards |
---|---|---|---|---|---|---|---|---|
Oct - Dec, 2023 | 82,386 | -31,247 | -49,064 | -49,967 | -125.8 | -37.9 | Jan 31, 2024 | IFRS |
Jan - Mar, 2024 | 79,530 | -237,114 | -217,923 | -197,261 | -496.5 | -298.1 | May 14, 2024 | IFRS |
Apr - Jun, 2024 | 90,675 | -3,105 | 17,203 | 15,937 | 40.1 | -3.4 | Jul 31, 2024 | IFRS |
Jul - Sep, 2024 | 90,074 | -5,074 | -49,609 | -48,166 | -121.2 | -5.6 | Oct 30, 2024 | IFRS |
Oct - Dec, 2024 | 112,434 | 21,405 | 56,432 | 53,448 | 134.5 | 19.0 | Jan 31, 2025 | IFRS |
YoY | +36.5% | - | - | - | - |
Related Articles
TOHO SYSTEM SCIENCE, Apr-Dec (Cumulative 3Q) Ordinary Profit Increases by 6%
Temairazu, First Half Ordinary Profit Increases by 9%, Oct-Dec Ordinary Profit Increases by 11%
KUNIMINE INDUSTRIES, Oct-Dec (3Q) Ordinary Profit Increases by 24%
Tokyo Kiraboshi Financial, Apr-Dec (Cumulative 3Q) Ordinary Profit Increases by 13%, Oct-Dec Ordinary Profit Increases by 31%
MEIDENSHA, The Current Fiscal Year Ordinary Profit Revised Upward by 19%, Raises Record High Profit Forecast
TDSE, The Current Fiscal Year Ordinary Profit Revised Upward by 35%
NSK, Apr-Dec (Cumulative 3Q) Net Income Decreases by 17%, Oct-Dec Net Income Decreases by 52%
ZEON, The Current Fiscal Year Ordinary Profit Revised Upward to an Unexpected 11% Increase
ZOZO, Apr-Dec (Cumulative 3Q) Ordinary Profit Increases by 13%, Oct-Dec Ordinary Profit Increases by 27%
NIPPON CHUTETSUKAN, The Current Fiscal Year Ordinary Profit Revised Downward by 17%